Liver Cancer

Positive Preclinical Data From Engineered Oncolytic Virus Therapy

Published in Cancer Weekly, October 9th, 2001

Cell Genesys, Inc. has reported that preclinical studies of CV890, an oncolytic virus engineered to target and destroy liver cancer cells, demonstrated significant synergistic antitumor activity in a mouse model when used in combination with Doxorubicin, a chemotherapeutic agent commonly used in the treatment of liver cancer.

In these studies, it was observed that human liver tumors in mice could be completely eliminated following a single intravenous injection of CV890 combined with Doxorubicin.

The preclinical studies evaluated CV890 and Doxorubicin therapy in mouse tumor models of human liver cancer referred to as human hepatoma xenografts. Since...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2001-10-09)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry